Eliaz Therapeutics, Inc is a Santa Rosa-based biotechnology company that is dedicated to developing a groundbreaking treatment using targeted therapeutic apheresis. Their mission is to revolutionize the treatment of life-threatening diseases, improving survival rates and preventing long-term disease and disability.
With a focus on addressing the common and potentially life-threatening condition of Acute Kidney Injury (AKI), Eliaz Therapeutics is developing a novel medical device that selectively removes galectin-3 from the bloodstream. Galectin-3 is a protein known to drive organ inflammation and fibrosis in various acute and chronic progressive conditions, and by targeting and removing it directly from the bloodstream, Eliaz Therapeutics aims to provide a much-needed solution to improve patient outcomes.
Generated from the website